S100A8 and acute kidney injury: They further targeted the S100a8/a9 by using small‐molecule inhibitors to successfully ameliorate renal damage and improve survival of the experimental AKI model, providing a promising and clinically relevant therapeutic strategy for human AKI.[46] In this study, the combination of multiple complementary technologies enables us to identify novel TLR4‐dependent downstream target, the Nr4a1/Ear2 feedback axis, in anti‐GBM cGN.